Virbac SA, the French animal health company listed on Euronext Paris Compartiment A under ISIN FR0000031577, has published its monthly declaration of the total number of shares and voting rights as required under Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. As at 30 October 2026, the company reported a total of 8,390,660 shares representing its share capital. The disclosure is a regulatory filing rather than a corporate transaction, but it provides investors with an up-to-date picture of the company's voting structure, which is relevant when assessing shareholder influence and governance dynamics.

Key Points

  • Virbac SA (0NM7), listed on Euronext Paris Compartiment A, ISIN FR0000031577, ticker VIRP
  • The company has published its statutory monthly declaration of shares and voting rights as at 30 October 2026
  • Total shares: 8,390,660; gross voting rights: 12,704,102; net voting rights: 12,695,066
  • Investors may watch for future changes in the voting rights figures as an indicator of shifts in shareholder concentration or treasury share activity

Virbac's October 2026 Share Capital and Voting Rights Figures Explained

The announcement states that as at 30 October 2026, Virbac SA's total share capital is represented by 8,390,660 shares. The gross total of voting rights stands at 12,704,102, while the net total of voting rights — calculated by excluding shares that carry no voting rights — is 12,695,066. The difference between the gross and net figures, amounting to 9,036 voting rights, reflects shares currently stripped of voting entitlement, most commonly treasury shares held by the company itself. This distinction is material to investors seeking to understand the effective distribution of voting power among active shareholders.

Regulatory Obligation Under AMF Article 223-16 Drives Monthly Filing

This declaration is made in accordance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, France's financial markets regulator. Under this rule, listed companies on Euronext Paris are required to publish monthly updates of their total voting rights and share capital figures, ensuring continuous transparency for investors and market participants. Virbac's filing is therefore a routine compliance exercise rather than an indication of any new corporate event. The company operates in the animal health sector, developing and marketing veterinary medicines, vaccines, and nutritional products for companion and food-producing animals globally.

Virbac's Dual Voting Right Structure Reflected in Share Capital Disclosure

The notable gap between Virbac's total share count of 8,390,660 and its gross voting rights figure of 12,704,102 suggests the company operates a double voting right structure, a mechanism permitted under French corporate law that grants additional voting rights to long-term registered shareholders. Such structures can concentrate effective voting control among loyal or founding shareholders relative to their economic ownership, a governance characteristic that investors monitoring Virbac's shareholder base and strategic decision-making should factor into their analysis of the company.

Animal Health Sector Context and Investor Considerations for Virbac

Virbac describes itself as "shaping the future of animal health," positioning the group within a growing global sector driven by rising pet ownership and increased veterinary care spending. The company's shares trade on Euronext Paris under the ticker VIRP, with corporate finance enquiries directed to its Nice, France headquarters. Investors tracking this stock may monitor subsequent monthly filings for movements in treasury share levels or voting rights balances that could signal buyback activity, share issuances, or changes in long-term shareholder positions over coming months.